01 April 2004
Treatment with HMG-CoA reductase inhibitors and fibrates results in a long-term reduction of markers of disease severity in PBC
Makoto Nakamuta, Kazuhiro Kotoh, Munechika Enjoji, Hajime NawataCase Rep Clin Pract Rev 2004; 5(null):537-541 :: ID: 428992
Abstract
Background: 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor as well as fibrate, lipid-lowering drugs, recently has been reported to reduce disease markers of primary biliary cirrhosis (PBC). Case Report: We report the long-term observation of a case of PBC treated sequentially with several lipidlowering drugs and the effects of these drugs on the liver function tests. A 39-year-old female was diagnosed as PBC because of liver dysfunction accompanying high levels of immunoglobulin M (IgM), positive antimitochondrial antibody (AMA), and histological findings as stage II of PBC. She was also diagnosed as familial hypercholesteremia (IIa) because of her family history. She was treated with ursodeoxycholic acid (UDCA), which led to a transient improvement in liver function tests. Consequently, she was sequentially given several lipid-lowering drugs, probucol, bezafibrate, pravastatin and atorvastatin in addition to UDCA because of high levels of cholesterol. Bezafibrate, pravastatin, and atrovastatin, but not probucol, reduce disease markers of PBC. Particularly, long-term treatment with atorvastatin for more than 2.5 years led to continuously improving most significantly, not only the colesterol levels, but also liver function tests including IgM and AMA, compared to the other lipid-lowering drugs used throughout the clinical course. There were no side effects throughout the treatment. Conclusions: Our case indicates that statins, as well as fibrates, could ameliorate PBC in the long-term without side effects, suggesting that statins may be a first-line treatment for PBC particularly in patients with hypercholesteremia.
Keywords: PBC, HMG-CoA reductase inhibitors, Statin, fibrates, Probucol, Multiple drug-resistant gene (MDR), Phospholipid, Ursodeoxycholic acid (UDCA)
25
In Press
12 Feb 2024 : Case report
Diagnostic Challenges and Imaging Considerations for Intraparotid Facial Nerve Schwannoma: A Case Report an...Am J Case Rep In Press; DOI: 10.12659/AJCR.942870
12 Feb 2024 : Case report
Erdheim-Chester Disease Occult on Radiographs and CT but Visible on MRI and PETAm J Case Rep In Press; DOI: 10.12659/AJCR.941169
12 Feb 2024 : Case report
Surgical Treatment of Spontaneous Superficial Temporal Artery Arteriovenous Malformation: A Case ReportAm J Case Rep In Press; DOI: 10.12659/AJCR.942839
13 Feb 2024 : Case report
Warfarin Woes: A Rare Case of Hemoperitoneum with Intramural Small Bowel HematomaAm J Case Rep In Press; DOI: 10.12659/AJCR.943519
Most Viewed Current Articles
10 Jan 2022 : Case report
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
19 Jul 2022 : Case report
Atlantoaxial Subluxation Secondary to SARS-CoV-2 Infection: A Rare Orthopedic Complication from COVID-19DOI :10.12659/AJCR.936128
Am J Case Rep 2022; 23:e936128
05 Mar 2022 : Case report
Acute Limb Ischemia After Self-Injection of Crushed Morphine Tablets into the Radial Artery: Role of Infrar...DOI :10.12659/AJCR.935336
Am J Case Rep 2022; 23:e935336
02 Apr 2022 : Case report
Infective Endocarditis Caused by Pseudomonas luteola in a Pediatric Patient. A Case Report and Review of Li...DOI :10.12659/AJCR.935743
Am J Case Rep 2022; 23:e935743